These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 9952368

  • 1. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
    Bostic JR, Brown KE, Young NS, Koenig S.
    J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
    [Abstract] [Full Text] [Related]

  • 2. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
    Corcoran A, Mahon BP, Doyle S.
    J Infect Dis; 2004 May 15; 189(10):1873-80. PubMed ID: 15122524
    [Abstract] [Full Text] [Related]

  • 3. An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell lines.
    Caillet-Fauquet P, Di Giambattista M, Draps ML, Hougardy V, de Launoit Y, Laub R.
    Transfusion; 2004 Sep 15; 44(9):1340-3. PubMed ID: 15318858
    [Abstract] [Full Text] [Related]

  • 4. Antibody-mediated opsonization of red blood cells in parvovirus B19 infection.
    Chehadeh W, Halim MA, Al-Nakib W.
    Virology; 2009 Jul 20; 390(1):56-63. PubMed ID: 19450862
    [Abstract] [Full Text] [Related]

  • 5. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.
    Beersma MF, Claas EC, Sopaheluakan T, Kroes AC.
    J Clin Virol; 2005 Sep 20; 34(1):71-5. PubMed ID: 15985386
    [Abstract] [Full Text] [Related]

  • 6. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
    Azzi A, Manaresi E, Zakrzewska K, DeSantis R, Musiani M, Zerbini M.
    J Med Virol; 2004 Apr 20; 72(4):679-82. PubMed ID: 14981773
    [Abstract] [Full Text] [Related]

  • 7. Human parvovirus B19 infection during pregnancy--value of modern molecular and serological diagnostics.
    Enders M, Schalasta G, Baisch C, Weidner A, Pukkila L, Kaikkonen L, Lankinen H, Hedman L, Söderlund-Venermo M, Hedman K.
    J Clin Virol; 2006 Apr 20; 35(4):400-6. PubMed ID: 16332455
    [Abstract] [Full Text] [Related]

  • 8. Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection.
    Kerr JR, Coyle PV, DeLeys RJ, Patterson CC.
    J Med Virol; 1996 Jan 20; 48(1):68-75. PubMed ID: 8825713
    [Abstract] [Full Text] [Related]

  • 9. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
    Von Landenberg P, Lehmann HW, Knöll A, Dorsch S, Modrow S.
    Arthritis Rheum; 2003 Jul 20; 48(7):1939-47. PubMed ID: 12847688
    [Abstract] [Full Text] [Related]

  • 10. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
    Lindner J, Barabas S, Saar K, Altmann D, Pfister A, Fleck M, Deml L, Modrow S.
    J Vet Med B Infect Dis Vet Public Health; 2005 Jul 20; 52(7-8):356-61. PubMed ID: 16316401
    [Abstract] [Full Text] [Related]

  • 11. Immune response to B19 parvovirus and an antibody defect in persistent viral infection.
    Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM, Young NS.
    J Clin Invest; 1989 Oct 20; 84(4):1114-23. PubMed ID: 2551923
    [Abstract] [Full Text] [Related]

  • 12. Development of an improved method of detection of infectious parvovirus B19.
    Wong S, Brown KE.
    J Clin Virol; 2006 Apr 20; 35(4):407-13. PubMed ID: 16455300
    [Abstract] [Full Text] [Related]

  • 13. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen.
    Heegaard ED, Rasksen CJ, Christensen J.
    J Med Virol; 2002 Jul 20; 67(3):375-83. PubMed ID: 12116031
    [Abstract] [Full Text] [Related]

  • 14. Antibody responses in parvovirus B19 infected patients.
    Modrow S, Dorsch S.
    Pathol Biol (Paris); 2002 Jun 20; 50(5):326-31. PubMed ID: 12116851
    [Abstract] [Full Text] [Related]

  • 15. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection.
    Pfrepper KI, Enders M, Motz M.
    J Vet Med B Infect Dis Vet Public Health; 2005 Jun 20; 52(7-8):362-5. PubMed ID: 16316402
    [Abstract] [Full Text] [Related]

  • 16. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
    Franssila R, Hedman K.
    Vaccine; 2004 Sep 09; 22(27-28):3809-15. PubMed ID: 15315862
    [Abstract] [Full Text] [Related]

  • 17. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay.
    Manaresi E, Gallinella G, Zerbini M, Venturoli S, Gentilomi G, Musiani M.
    J Med Virol; 1999 Feb 09; 57(2):174-8. PubMed ID: 9892404
    [Abstract] [Full Text] [Related]

  • 18. Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood.
    Lehmann HW, Knöll A, Küster RM, Modrow S.
    Arthritis Rheum; 2003 Jun 09; 48(6):1631-8. PubMed ID: 12794831
    [Abstract] [Full Text] [Related]

  • 19. The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production.
    Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS, Hsu TC.
    Clin Chim Acta; 2007 Mar 09; 378(1-2):59-65. PubMed ID: 17169353
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
    Ballou WR, Reed JL, Noble W, Young NS, Koenig S.
    J Infect Dis; 2003 Feb 15; 187(4):675-8. PubMed ID: 12599085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.